Leeder JS - Search Results

1

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC; Clinical Pharmacogenetics Implementation Consortium. Crews KR, et al. Among authors: leeder js. Clin Pharmacol Ther. 2014 Apr;95(4):376-82. doi: 10.1038/clpt.2013.254. Epub 2014 Jan 23. Clin Pharmacol Ther. 2014. PMID: 24458010 Free PMC article.

2

Epitope mapping studies with human anti-cytochrome P450 3A antibodies.

Leeder JS, Gaedigk A, Lu X, Cook VA. Leeder JS, et al. Mol Pharmacol. 1996 Feb;49(2):234-43. Mol Pharmacol. 1996. PMID: 8632755

3

Tissue-specific expression and alternative splicing of human microsomal epoxide hydrolase.

Gaedigk A, Leeder JS, Grant DM. Gaedigk A, et al. Among authors: leeder js. DNA Cell Biol. 1997 Nov;16(11):1257-66. doi: 10.1089/dna.1997.16.1257. DNA Cell Biol. 1997. PMID: 9406998

4

Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions.

Leeder JS, Lu X, Timsit Y, Gaedigk A. Leeder JS, et al. Pharmacogenetics. 1998 Jun;8(3):211-25. doi: 10.1097/00008571-199806000-00004. Pharmacogenetics. 1998. PMID: 9682267

5

Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.

Henne KR, Gaedigk A, Gupta G, Leeder JS, Rettie AE. Henne KR, et al. Among authors: leeder js. J Chromatogr B Biomed Sci Appl. 1998 Jun 12;710(1-2):143-8. doi: 10.1016/s0378-4347(98)00099-1. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9686881

6

NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations.

Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. Gaedigk A, et al. Among authors: leeder js. Pharmacogenetics. 1998 Aug;8(4):305-13. doi: 10.1097/00008571-199808000-00004. Pharmacogenetics. 1998. PMID: 9731717

7

Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.

Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, Gaedigk A, Bertino JS Jr. Kashuba AD, et al. Among authors: leeder js. Pharmacogenetics. 1998 Oct;8(5):403-10. doi: 10.1097/00008571-199810000-00005. Pharmacogenetics. 1998. PMID: 9825832

8

Investigation of terbinafine as a CYP2D6 inhibitor in vivo.

Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL. Abdel-Rahman SM, et al. Among authors: leeder js. Clin Pharmacol Ther. 1999 May;65(5):465-72. doi: 10.1016/S0009-9236(99)70065-2. Clin Pharmacol Ther. 1999. PMID: 10340911 Clinical Trial.

9

Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.

Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Abdel-Rahman SM, et al. Among authors: leeder js. Drug Metab Dispos. 1999 Jul;27(7):770-5. Drug Metab Dispos. 1999. PMID: 10383919

10

High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data.

Bradford LD, Gaedigk A, Leeder JS. Bradford LD, et al. Among authors: leeder js. Psychopharmacol Bull. 1998;34(4):797-804. Psychopharmacol Bull. 1998. PMID: 10513455 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters